The 13th Annual
Peptide Therapeutics
Symposium

The Salk Institute – La Jolla, CA
October 25 – 26, 2018

Register Now
Sponsors

Past Symposia

12th Annual Peptide Therapeutics Symposium, October 2017

Cellular Manipulation through Cell Penetrating Peptide-Loaded Exosome Transfer
Jason K. Allen and Jean-Philippe Pellois
Department of Biochemistry and Biophysics, Texas A&M University

A Novel One-Pot Synthesis Strategy for Bicyclic Peptide Assembly
Angell Yvonne, Y. Wang
Department of Peptide Chemistry, ChemPartner SF

ORBIT Peptide Display—High throughput Selection of Peptides with Biological Function
Alex Batchelor, Graham Ogg
Orbit Discovery Ltd

Efficient Cell Aelivery and Lipid-specific Endosomal Escape by Aupercharged Peptides
Dakota Brock, Lauren Kustigian, Menqgiu Jian, Junjie Zhang, Hays Rye, Jean-Philippe Pellois
Texas A&M University

Effect of a Fusion Peptide by Covalent Conjugation of a Mitochondrial Cell-penetrating Peptide and a Glutathione Analog Peptide
Carmine Pasquale Cerrato, and Ülo Langel
Department of Neurochemistry, the Arrhenius Laboratories for Natural Sciences, Stockholm University

MOE Coupled with AutoDock Vina Molecular Docking and Virtual Screening Empowered Discovery of Tetrapeptides Inhibitors of Y-49 β-Lactamase
Cristina Clement, Janet Gonzalez, Manfred Philipp
Natural Sciences, LaGuardia Community College

Genetically Encoded Discovery of Chemically-Modified Peptides
Ratmir Derda
Department of Chemistry, Alberta Glycomics Centre, University of Alberta

Scaffold-based Citrullinated Peptides for Inhibition of Autoantibodies in Rheumatoid Arthritis
Camilla Eriksson, Sunithi Gunasekera, Cátia Fernandes-Cerqueira, Per-Johan Jakobsson and Ulf Göransson
Uppsala University, Department of Medicinal Chemistry, Division of Pharmacognosy, Biomedical Centre, Uppsala University

Towards Mild and Selective Incorporation of Freidinger Lactams into Expressed Peptides
Dillon Flood and Philip E. Dawson
The Scripps Research Institute

GUB06-046, a Novel Secretin/GLP-1 Co-Agonist, Decreases Food Intake, Improves Glycemic Control and Preserves Beta Cell Mass in db/db Mice
Keld Fosgerau, Søren B. van Witteloostuijn, Louise S. Dalbøge, Gitte Hansen, Knud J. Jensen, Niels Vrang,
Jacob Jelsing and Søren L. Pedersen
Department of Chemistry, University of Copenhagen

Machine Learning Techniques for Peptide Optimization from Sequence Information
Mark R. Hansen, Evgenia Razumovskaya, Jason Hodges, Hugo O Villar
Altoris, Inc. San Diego, CA; UC San Diego

Fast Synthesis of 84-mer Human Parathyroid Hormone for the Study of Osteoporosis and Hypoparathyroidism
Katya Karankevich, Daniel Martinez, Cyf Ramos-Colón and James P. Cain
Gyros Protein Technologies

A Novel Tri-Peptide Elicits Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury by an Opioid Receptor Mechanism
Hanna Kim, Anahi McIntyre, John Woodley, Alexandra Lopez, Tejaswi Dittakavi, Matt Finnegan, Kevin Amuquandoh, Maxwell Ambrosino, Kiana Walker, Harsh Patel, Qian Chen, Robert Barsotti, Lindon H. Young
Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine

Designing Cell-material Interactions by Controlling the Chemistry of the Surface of Degradable Porous Scaffolds
Tove Kivijärvi, Daniela Pappalardo, Anna Finne-Wistrand
Department of Fibre and Polymer Technology, KTH Royal Institute of Technology; Department of Science and Technology, University of Sannio

Modulation of Quorum Sensing in Streptococcus pneumoniae; An Alternative Approach to Antimicrobial Therapy
Bimal Koirala, Naiya R. Phillips, Sally R. Hamry, Yftah Tal-Gan
Department of Chemistry, University of Nevada

Characterizing the Impact of the Highly Endosomolytic Cell-Penetrating Peptide, dfTAT, on
Human Cells
Helena M. Kondow and Jean-Philippe Pellois
Department of Biochemistry and Biophysics, Texas A&M University

Investigation of Novel Cyclic Peptides for Preferential Binding to Melanocortin 4 Receptors
Maj Krumberger, C.A. Page, J. L. Rios-Monterrosa, Y. Zhou, S. Mowlazadeh Haghighi, M. Cai, V.J. Hruby
University of Arizona

Mapping Membrane Activity in Undiscovered Peptide Sequence Space Using Machine Learning
Ernest Y. Lee, Benjamin M. Fulan, Gerard. C. L. Wong, Andrew L. Ferguson
Department of Bioengineering, University of California, Los Angeles; Department of Mathematics; Materials
Science and Engineering; and Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign

On the Effects of Acylation of Cell-penetrating Peptides in Nucleic Acid Delivery In Vitro and In Vivo
Tõnis Lehto, Kadi-Liis Veiman, Helerin Margus, Kaido Kurrikoff, Margus Pooga, Mattias Hällbrink, Ülo Langel
Department of Neurochemistry, The Svante Arrhenius Laboratories for Natural Sciences, Stockholm University; Institute of Molecular and Cell Biology, University of Tartu; Institute of Technology, University of Tartu

Effective Prediction of Long-term Stability and Aggregation Propensity of Proteins via Differential Scanning Calorimetry (DSC)
Yingkai Liang, Grace Okoh, Erika Walsh, Andrew Leithead, Nicole Buist
Discovery Pharmaceutical Sciences, Merck & Co., Inc.; Oral Formulation Science & Technology, Formulation Sciences, Merck & Co., Inc.

Evaluation of Apelin-13 Analogues as Antidiabetic Therapeutics
Charlotte S. Madsena, Esben M. Becha, Rikke V. Grønlunda, Gitte Hansena, Søren L. Pedersena, Keld Fosgeraua
Gubra ApS

Myristoylated Protein Kinase C Epsilon Peptide Inhibitor Reduces Infarct Size and Improves Cardiac Function Following Myocardial Ischemia/Reperfusion (I/R)
Anahi McIntyre, Christine Adekayode, Hanna Kim, John Woodley, Tejaswi Dittakavi, Matt Finnegan, Joseph Heron, Ifeanyi James, Israel Benjamin, Stephanie Liu, Kiana Walker, Qian Chen, Robert Barsotti, Lindon H. Young
Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine

CPP and Small Molecule Synergy Enhances Endosomal Escape and Cytosolic Delivery in Live Cells
Kristina Najjar, Alfredo Erazo-Oliveras, Rudolph L. Juliano, and Jean-Philippe Pellois
Department of Biochemistry and Biophysics, Texas A&M University; Department of Nutrition and Food Science, Texas A&M University; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill; and Department of Chemistry, Texas A&M University

Optimizing Peptide Manufacturing on the Small Scale and its Application in the Rapid Development of New Personalized Medicines
Porter, Keith, Jonathan Collins, S. Sub Singh, Michael Karney
CEM Corporation

Novel Therapeutic Peptides Targeting Matricellular Signaling in Currently Untreatable Fibrotic Disease and Cancer
Bruce L. Riser, Dorina Belotti, and Giulia Taraboletti
BLR Bio LLC; The Department of Physiology and Biophysics, and Department of Medicine, Rosalind Franklin University of Medicine and Science; and Mario Negri Institute of Pharmaceutical Research

Improved Florescent Amino Acids For In Situ Labeling of Bacterial Cell Walls
Jonathan Rittichier, Erkin Kuru1, Yen-Pang Hsu, Yves V. Brun, Michael S. VanNieuwenhze, and George M. Church
Harvard Medical School; Indiana University

Development of a New Method on Npys-based Disulfide Bond Formation for the Preparation of Bioactive Cyclic Disulfide Peptides
Akihiro Taguchi, Kiyotaka Kobayashi, Akira Kotani, Kyohei Muguruma, Misaki Kobayashi, Kentarou Fukumoto, Kentaro Takayama, Atsuhiko Taniguchi, Hideki Hakamata, Yoshio Hayashi1
Department of Medicinal Chemistry and Department of Analytical Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences; Kokusan Chemical Co., Ltd.

Discovery of Selective Hexapeptide Agonists to Human NMUR1 and NMUR2
Kentaro Takayama, Kenji Mori, Akiko Tanaka, Akihiro Taguchi, Atsuhiko Taniguchi, Toshiyasu Sakane, Akira Yamamoto, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi
Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences; Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute; Department of Biopharmaceutics, Kyoto Pharmaceutical University; Laboratory of Pharmaceutical Technology, Kobe Pharmaceutical University; and Omics Research Center, National Cerebral and Cardiovascular Center

Highly Efficient Synthesis of Therapeutic Macrocyles by Ligases
James P. Tam and Xinya Hemu
Nanyang Technological University, School of Biological Sciences

Computational Design and Experimental Characterization of Peptides Intended for pH-Dependent Membrane Insertion and Pore Formation
David Tellers
Merck and Co., Inc.

Plasma Protein Binding Analysis of Peptides with a Novel Single-compartment Mass Spectrometry Assay
Jan Ungewiss, Hinnerk Boriss
3B Pharmaceuticals GmbH; Sovicell GmbH

Targeting Quorum Sensing in Streptococcus Pneumoniae: An Alternative Antibacterial Approach
Yifang Yang, Bimal Koirala, Lucia A. Sanchez, Gabriel Cornilescu, and Yftah Tal-Gan
Department of Chemistry, University of Nevada, Reno; National Magnetic Resonance Facility at Madison,
University of Wisconsin-Madison

N-linked Glycosylation Prevents Deamidation of Glycopeptide and Glycoprotein
Hailiang Zhu, Ding Liu, Vy P Tran, Zhigang Wu, Kuan Jiang, He Zhu, Xu Li, Xifang Liu, Jingyao Qu, Bingzhong Xue, Hang Shi, and Peng George Wang
Department of Chemistry, Georgia State University; Department of Biology, Georgia State University; Department of Chemistry, Dordt College

Structure-Based Design, Synthesis and Evaluation of Constrained Seven Membered Ring-Containing Tetrapeptides Lead to Selective Human Melanocortin 1 Receptor
S. Mowlazadeh Haghighi, Y. Zhou, J.R. Sawyer, A.C. Ho, J. Rios- Monterrosa, V.J. Hruby, M. Cai
Department of Chemistry and Biochemistry, University of Arizona

11th Annual Peptide Therapeutics Symposium, October 2016

Asprosin, a Fasting-Induced Glucogenic and Orexigenic Protein Hormone
Atul Chopra, M.D., Ph.D.,  Caroline Wiess Law Scholar, Assistant Professor, Department of Molecular and Cellular Biology, Department of Molecular and Human Genetics, Baylor College of Medicine

Tailoring Peptides for less Frequent Dosing and Non-invasive Delivery
Jesper Lau, Ph.D., Vice President, Diabetes Protein and Peptide Chemistry, Diabetes Research Unit, Novo Nordisk A/S

Non- Peptide GLP-1 Receptor Agonists; From Idea to Medicine
Carmen Valcarce, Ph.D., Senior Vice President and Chief Scientific Officer, vTv Therapeutics

Structural Elucidation of Ligand Binding Sites in Class B GPCRs and their Application in Drug Discovery
Ali Jazayeri, Ph.D., Chief Technology Officer, Heptares Therapeutics

Selective Inhibition of Cytokines with Peptide Therapeutics: A Unique Alternative to Conventional MAB and JAK Inhibitor Approaches for Cytokine Modulation
Nazli Azimi, Ph.D., Founder, President and CEO, Bioniz Therapeutics, Inc.

Peptide-based Strategies to Treat Inflammatory and Autoimmune Diseases: From the Peptide P140 to Lupuzor™
Sylviane Muller, Ph.D., Professor and CNRS Director, Molecular and Cellular Biology Institute, University of Strasbourg

Innovation by Evolution: Expanding the Enzyme Universe
Frances H. Arnold, Ph.D., Dickinson Professor of Chemical Engineering Bioengineering and Biochemistry, Division of Chemistry and Chemical Engineering, California Institute of Technology

Novel Synthetic Strategies for Insulin and Related Peptides
Fa Liu, Ph.D.,  Director of Chemistry, Novo Nordisk Research Center-Indianapolis

AB103: Host-Oriented Therapeutics to Control Life Threatening Infections
Anat Shirvan, Ph.D., Executive Vice President, Research & Development, Atox Bio, Ltd.

Engineering Potent and Selective Inhibitors of Nav1.7 Sodium Channel
Les Miranda, Ph.D., Director Research, Hybrid Modality Engineering, Structural Biology, & Molecular Modeling, Therapeutic Discovery, Amgen Inc.

Taregting Novel Polysaccharide-binding Proteins to Block Tissue Fibrosis
Eva Turley, Ph.D., Chief Scientist, Novare Pharmaceuticals

TLQP-21 and C3aR1, a Novel Ligand/Receptor Target for Lipolysis and Obesity
Alessandro Bartolomucci, Ph.D., Associate Professor of Physiology, Department of Integrative Biology and Physiology, University of Minnesota

Discovery and Clinical Development of Elamipretide
Hazel H. Szeto, M.D., Ph.D., Adjunct Professor, Weill Cornell Medicine

Unlocking the Mysteries of Amyloid Diseases with Macrocyclic β-Sheet Peptides
James S. Nowick, Ph.D., Professor of Chemistry and Department Chair, University of California, Irvine

Endocrine FGFs and Structure-Activity-Relationship
Alexei Kharitonenkov, Ph.D., Professor, Department of Chemistry, Indiana University

New Therapeutics from the Human Microbiome: Discovery of Novel Proteins and Peptides for the Treatment of Gastrointestinal Barrier Related Disorders
Karim Dabbagh, Ph.D., Chief Scientific Officer, Second Genome, Inc.

Chemo-enzymatic Peptide Synthesis (CEPS): A Generally Applicable, Traceless Ligation Technology for the Synthesis of Peptide-to-peptide and Peptide-to-protein Conjugates
Timo Nuijens, Ph.D., Lead Scientist, EnzyPep

InGell® – Injectable Drug Depots for Short and Mid-term Release of Soluble and Non-soluble API’s
Mike G.W. de Leeuw, MSc, BBA, Founder and Chief Business Officer, InGell Labs BV

Errata located at the end of the Symposium PDF

10th Annual Peptide Therapeutics Symposium, October 2015

Building Better Medicines: Translational Research in the 21st Century
Roger M. Perlmutter, M.D., Ph.D.  Executive Vice President and President, Merck Research Laboratories

An Integrated View of the Adipocyte: From Feast to Famine
Philipp E. Scherer, Ph.D.  Professor, Department of Internal Medicine, Gifford O. Touchstone Jr. and
Randolph G. Touchstone Distinguished Chair in Diabetes Research; Director,
Touchstone Diabetes Center, The University of Texas Southwestern Medical Center

Oral Peptide Delivery: Deciphering the Reality from the Hype
David J. Brayden, Ph.D.  Professor of Advanced Drug Delivery, University College Dublin

Oral Inhalation – A Simple Approach to Biologics Delivery
John Freeman, M.S.  Principal Scientist, MannKind Corporation

ITCA 650 (Exenatide Delivered Continuously via a Matchstick-Size Subcutaneous
Osmotic Mini-Pump) an Investigational Therapy for Type-II Diabetes
Scott Peterson, Ph.D.  Executive Director, Corporate Development, Intarcia Therapeutics, Inc.

MICROCOR® Transdermal System: Technology Overview and Clinical Status
Bobby Singh, Ph.D.  Chief Technology Officer, Corium International, Inc.

Activity-based Proteomics – Applications for Enzyme and Inhibitor Discovery
Benjamin F. Cravatt, Ph.D.  Professor and Chair, Department of Chemical Physiology, The Scripps Research
Institute

Molecular Targets for the Effects of Bariatric Surgery on Obesity and Diabetes
Randy J. Seeley, Ph.D.  H.K. Ransom Professor of Surgery, University of Michigan

Harnessing Chemistry and Glycoproteins to Discover Novel Targets for Cancer
Therapy and Neurodegenerative Diseases
Linda C. Hsieh-Wilson, Ph.D.  Professor of Chemistry, Division of Chemistry and Chemical Engineering, California
Institute of Technology

Engineered Cystine Knot Peptides: A New Class of Tumor Targeting Agents
Jennifer R. Cochran, Ph.D.  Associate Professor, Department of Bioengineering, and (by courtesy) Chemical
Engineering, Stanford University

Phage Selection of Bicyclic Peptides for Application as Therapeutics
Christian Heinis, Ph.D.  Assistant Professor, École Polytechnique Fédérale de Lausanne (EPFL)

Kisspeptin and its Short-length Agonist Analogues: Discovery and Development
Taiji Asami, Ph.D.  Associate Director, Takeda Pharmaceutical Company Ltd.

Phage-display Derived Peptidic Inhibitors of PCSK9 for LDL Cholesterol Lowering
Daniel Kirchhofer, Ph.D.  Principal Scientist, Department of Early Discovery Biochemistry, Genentech, Inc.

Improved Chemical and Physical Stability in Liquid Formulations – How to Design
Stable Glucagon Analogues
Lise Giehm, Ph.D.  Senior Scientist, Department of Pharmaceutical Development, Zealand Pharma A/S

Selepressin, a Selective hV1a Agonist for the Treatment of Hypotension in Septic Shock
Claudio D. Schteingart, Ph.D.  Director, Peptide Therapeutics Foundation
Vice President, Science & Technology – Research, Ferring Research Institute Inc.

Addressing the Challenges with the Discovery and Development of Peptide
Therapeutics
Paul L. Feldman, Ph.D.  Head of Discovery and Translational Medicine, Intarcia Therapeutics Inc.
Former CEO & Co-founder, Phoundry Pharmaceuticals

NA-1: From Bench to Bedside – A Novel Peptide Therapeutic for the Treatment of
Acute Stroke
Dave Garman, Ph.D.  Technology Officer, NoNO Inc.

Relamorelin, a Ghrelin Agonist for the Treatment of Diverse Functional
Gastrointestinal Disorders
Lex H.T. Van der Ploeg, Ph.D.  Chief Scientific Officer, Rhythm Pharmaceuticals

9th Annual Peptide Therapeutics Symposium, October 2014

Multiselective Peptides for the Treatment of Metabolic Diseases by Cristina Rondinone, Ph.D., Vice President, Research and Development, Head Cardiovascular/Metabolic Diseases iMED, Medimunne

Peptide Agonists of Incretin Receptors Are High Priority Candidates in the Search for the First Effective Treatments of Alzheimer’s Disease by Konrad Talbot, Ph.D., Associate Professor, Department of Neurosurgery, Cedars-Sinai Medical Center

Continuous Glucose Monitoring: Technology that will Bridge the Gap until there is a Cure for Type 1 Diabetes by Steven Edelman, M.D., Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center , Founder and Director, Taking Control of Your Diabetes 501(c)3

Peptide Therapeutics: A New Golden Age by Richard A. Houghten, Ph.D., Founder, President & CEO, Torrey Pines Institute for Molecular Studies

New Physiology and Pharmacology of the Melanocortin-4 Receptor by Roger D. Cone, Ph.D.,Professor and Chair, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center

Chemoenzymatic Approaches in Amide-to-amide Peptide Ligation by James P. Tam, Ph.D. , Professor, Herbalomics and Drug Discovery, School of Biological Sciences, Nanyang Technological University

Hepcidin and Minihepcidins: From Mechanistic Studies to Therapeutic Peptides by Tomas Ganz, Ph.D., M.D., Professor of Medicine and Pathology, University of California, Los Angeles

Discovery of Functional Ligands and Materials from Genetically-encoded Libraries of Chemically-modified Peptides by Ratmir Derda, Ph.D.,Assistant Professor, Department of Chemistry and Alberta Glycomics Centre, University of Alberta

Using the Endosome Escape Trap to Discover Phylomer Peptides which more Efficiently Deliver Cargoes to the Cytoplasm by Paul Watt, D.Phil., Chief Scientific Officer, Phylogica Ltd

Danegaptide – Potential First and Best in Class Peptide Medicine for Prevention of Myocardial Reperfusion Injury by Rie Schultz Hansen, MSc, Ph.D. , Principal Scientist, Zealand Pharma A/S

Arylomycin Antibiotics by Floyd E. Romesberg, Ph.D., Assistant Professor, Department of Chemistry The Scripps Research Institute

Novel Peptide Therapeutics Targeting Key Intracellular Signaling Pathways of Cancer Stem Cells by Jörg Vollmer, Ph.D., Managing Director and Chief Executive Officer, Nexigen GmbH

Peptide Antagonists of the Inflammatory Response Enhanced by the Antimicrobial Peptide LL-37 by Cheng Kao, Ph.D. , Director of Biotechnology and Professor, Department of Molecular & Cellular Biology, Indiana University

Integrated Triple Gut Hormone Action Broadens the Therapeutic Potential of Endocrine Biologics for Metabolic Diseases by Brian Finan, Ph.D. Division Head, Helmholtz Zentrum Munich

8th Annual Peptide Therapeutics Symposium, October 2013

The Structural and Energetic Basis of Carbohydrate–Polypeptide Stabilizing Interactions Within Enhanced Aromatic Sequons in Protein Native States by Jeffery W. Kelly, The Scripps Research Institute

Developing IMS-MS Techniques as a means of Following Structural Transitions of Biopolymers in Solution by David E. Clemmer, Indiana University

Half-Life Extension Through HESylation® by Martin Meyer, Fresenius Kabi Deutschland GmbH

Long-acting Release of Drug Peptides by in situ Gelling FluidCrystal® Injection Depot by Fredrik Tiberg, Camurus AB

The Transdermal Delivery of Peptides and other Biotherapeutics by Frank Tagliaferri, 4P Therapeutics

Structural Insights into HIV, Influenza & HCV Antigen Design by Ian A. Wilson, The Scripps Research Institute

How Insulin Binds: Structure of a Micro-receptor Complex and Implications for Analog Design by Michael A. Weiss, Case Western Reserve University

Mimicry of Hormone Recognition Surfaces with Peptidic Foldamers by Samuel H. Gellman, University of Wisconsin, Madison

ShK-186, a Peptide Inhibitor of Kv1.3 Potassium Channels as Therapy for Autoimmune Diseases and Metabolic Syndrome by K. George Chandy, University of California, Irvine

The Tale of Two Peptides Rescuing a Company in Distress by Roger J. Garceau, NPS Pharmaceuticals, Inc.

Towards Optimized Utility of Proteasome Inhibitors with Peptide Epoxyketones by Christopher J. Kirk, Onyx Pharmaceuticals, Inc.

Direct Selection of Highly Potent Cyclic Peptidomimetics from In Vitro Display Libraries by Douglas A. Treco, Ra Pharmaceuticals, Inc.

Development of Serelaxin for Acute Heart Failure by Dennis Stewart, Corthera Inc., Novartis Pharmaceuticals Corp.

SOM230: A New Therapeutic Modality for Cushing’s Disease by Ian Lewis, Novartis Institutes of Biomedical Research

PeptiDream’s PD Platform: Innovative Peptide Discovery Platform by Patrick C. Reid, Peptidream Inc.

Design of Peptide Therapeutics Exhibiting Dual Pharmacology and Extended Duration of Action by Soumitra Ghosh, Amylin Pharmaceuticals LLC

The Development of BA058, a Novel Peptide, for the Treatment of Osteoporosis by Gary Hattersley, Radius Health, Inc.

99mTc-Galacto-RGD2: A novel 99mTc-Labeled Cyclic RGD, Peptide Dimer Useful for Tumor Imaging by  Michael Pennington, Peptides International, Inc.

View Program
View Digital Copy

7th Annual Peptide Therapeutics Symposium, October 2012

Chemoselective Strategies for the Synthesis of Complex Assemblies of Peptide by
Philip Dawson, Ph.D., Associate Professor of Cell Biology & Chemistry, The Scripps Research Institute

Cell-penetrating Peptides with Intrinsic Biological Activity by Francesca Milletti, Ph.D., Head, Cheminformatics & Statistics, Roche Pharmaceuticals

Peptide Macrocyclization Enabled by Amphoteric Molecules by Andrei K. Yudin, Ph.D., Professor, Davenport Research Laboratories, Chemistry Department,
University of Toronto

The State of Pharmaceutical Innovation by Bernard Munos, MBA, Founder, InnoThink Center for Research in Biomedical Innovation

Design of Therapeutics that Act on Membranes and Membrane Proteins by Bill DeGrado, Ph.D., Professor, Department of Pharmaceutical Chemistry; Investigator, Cardiovascular
Research Institute, University of California, San Francisco

Gut-peptide Based Poly-pharmacy for the Treatment of Obesity & Diabetes by Matthias Tschöp, M.D., Alexander-von-Humboldt Professor; Director, Institute for Diabetes and
Obesity, German Center for Diabetes Research, Helmholtz Center Munich

Omontys: Beating the Odds in the Journey of a Drug from Bench to Bedside
Anne-Marie Duliege, M.D., M.S., Chief Medical Officer, Affymax, Inc.

Identification and Characterization of KAI-4169, A Novel Peptide for the Treatment
of Secondary Hyperparathyroidism by Gregory M. Bell, M.D., Senior Vice President, Development, KAI Pharmaceuticals

Stapled Peptide Drugs: Translation to the Clinic by Tomi K. Sawyer, Ph.D., Chief Scientific Officer and Senior-Vice President, Drug Discovery and Innovative
Technologies, Aileron Therapeutics

LY2605541, a Novel Long-acting Basal Insulin by Mel Prince, M.D. Senior Medical Director, Lilly Diabetes, Eli Lilly and Company

NMDA Receptor Modulating Peptides with Therapeutic Potential: From Monoclonal Antibodies to the Creation and Development of GLYX-13 by Joseph R. Moskal, Ph.D., Professor and Director, The Falk Center for Molecular Therapeutics, McCormick School of Engineering and Applied Sciences, Dept. of Biomedical Engineering, Northwestern University

XEP-018: A New Myorelaxant Peptide Lead Compound from the Venom of the
Cone Snail Conus consors by Reto Stöcklin, Ph.D., President & CEO, Research & Development, Atheris Laboratories

XTENylation Offers a Biodegradable Alternative to PEGylation by Volker Schellenberger, Ph.D., Chief Scientific Officer, Amunix, Inc.

Tunable Half-life Extension of Therapeutics by Controlled Chemical Release from
Macromolecular Conjugates by Daniel V. Santi, M.D., Ph.D., President, ProLynx LLC; Professor, University of California, San Francisco

Development of Modified Human Serum Albumins for Peptide and Protein Half-life Extension: Towards Monthly Dosing by Mark Perkins, Ph.D., Customer Solutions Manager, Novozymes Biopharma UK Ltd.

Clinical Development of a Novel PTH Analog for the Treatment of Osteoporosis with an
Optimized Oral Tablet Formulation by Nozer Mehta, Ph.D., Vice President, Research and Development, Unigene Laboratories, Inc.

View Digital Copy

6th Annual Peptide Therapeutics Symposium, October 2011

Discussion about factors driving R&D funding today
Hans-Joachim Böhm, Ph.D.Director, Peptide Therapeutics Foundation, Global Head of Chemistry, Roche; Center Manager, Roche Pharma Research & Early Development Site Basel
Stan Crooke, M.D., Ph.D., Chairman of the Board and CEO, Isis Pharmaceutical, Inc.
Rodney Lappe, Ph.D., Director, Peptide Therapeutics Foundation, Group Sr. Vice President, Pfizer Worldwide Research & Development; Chief Scientific Officer, CovX Research

Development of a Long-acting C-peptide (ErsattaÔ) by James Callaway, Ph.D. President and CEO, Cebix Incorporated
Michel Pettigrew, MBA, President of the Executive Board & Chief Operation Officer, Ferring Pharmaceuticals

Long Acting Y2R Peptide Mimetic as a New Generation Therapeutic Agent for the Management of T2D by Waleed Danho, Ph.D., Distinguished Research Leader, Hoffmann- La Roche Inc.

Somatostatin-Dopamine Chimeric Molecule for Potential Treatment of Pituitary Adenomas and Neuroendocrine Tumors by Jesse Z. Dong, Ph.D., Director, Peptide Therapeutics Foundation, Vice President, Compound Discovery, Ipsen
An Expanding Genetic Code by Peter Schultz, Ph.D., Scripps Family Chair Professor, Department of Chemistry, The Scripps Research Institute

Targeting Protein Therapeutics Across the Blood-Brain Barrier with Molecular Trojan Horses by William M. Pardridge, Ph.D., Distinguished Professor of Medicine, University of California, Los Angeles

Neuropeptidomics: From the Discovery of New Neuropeptides to the Elucidation of their Functions by Jonathan Sweedler, Ph.D., Professor of Chemistry, James R. Eiszner Family Chair, University of Illinois, Urbana-Champaign

Comparative Peptidomic Analysis for Functional Discovery of Neuropeptides by Lingjun Li, Ph.D., Professor, School of Pharmacy and Department of Chemistry, University of Wisconsin

High Resolution Mass Spectrometry-Based Profiling of Secreted Peptides for Drug Discovery by Steven Taylor, Ph.D.
Director of Chemistry, Amylin Pharmaceuticals; Research Associate, Scripps Institution of Oceanography

EPiC Technology: Using Peptide to Physiologically Cross the BBB by Jean Paul Castaigne, M.D., MBA, President and CEO, AngioChem

Endogenous Peptides to Safely Enhance the Delivery of (peptide) Drugs to the Brain by Willem van Werperen, MSc, MBA, CEO, to-BBB

Enhancing CNS Uptake of Biologics through Molecular Engineering by Ryan Watts, Ph.D., Associate Director, Head of Neurodegeneration Labs, Department of Neuroscience, Genentech, Inc.

NPY2R Selective Peptide Agonists for the Treatment of Obesity: Balancing Efficacy, Time Action and Cardiovascular Profile by Jordi Alsina, Ph.D., Senior Research Scientist, Eli Lilly & Company

Development Of CR845, a Novel, Peripherally-Acting Peptidic Kappa Opioid Agonist, for the Treatment of Postoperative Pain by Derek Chalmers, Ph.D., D.Sc., President & CEO, Cara Therapeutics, Inc.

ZYPH0907: A Novel Orally Active PTH1R Agonist for Treatment of Osteoporosis by Mukul Jain, Ph.D.,Senior Vice President, ZydusResearch Center

5th Annual Peptide Therapeutics Symposium, October 2010

Venture Capital panel discussion: Attractive Financing Structures for Emerging Biotechnology Companies.
John Diekman, Ph.D., Founder & Managing Partner, 5AM Ventures
Shehan Dissanayake, PhD, CEO, Tavistock Life Sciences
Malcolm Finlayson, Ph.D., Venture Partner, Hamilton Bioventures
Pratik Shah, Ph.D., Venture Partner, Thomas, McNerney & Partners

Chemical Synthesis in the Development of Protein Therapeutics by Stephen B.H. Kent, Ph.D., Professor, Department of Chemistry, University of Chicago

Chemically Programmed Immunity: Making Peptides Drugs and More by Carlos Barbas III, Ph.D., Janet and Keith Kellogg II Chair in Molecular Biology Professor, Department of Molecular Biology, The Scripps Research Institute

Tumor-penetrating Peptides in Targeted Tumor Treatment by Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor, Sanford-Burnham Medical Research Institute

Glioblastoma: Cancer Stem Cells and Reprogramming by Inder Verma, Ph.D., Professor, Irwin and Joan Jacobs Chair in Exemplary Life Science, Laboratory of Genetics and American Cancer Society Professor of Molecular Biology, Salk Institute for Biological Studies

From Combinatorial Chemistry to Nanoparticles to Cancer Imaging and Therapy by Kit Lam, M.D., Professor and Chief, Hematology and Oncology, University of California Davis Cancer Center

Protein Engineering: A Key Innovation Path for Novel Biopharmaceuticals by Thomas Bumol, Ph.D., President, Applied Molecular Evolution & Vice President Biotechnology, Lilly Research Laboratory

Early Clinical Development of Novel Biologics by Richard Jones, M.D., Chief Medical Officer, Syntaxin

Ligand-receptor Fusions for the Generation of Long-acting Biopharmaceuticals by Richard Ross, M.D., Chief Scientific Officer and Director, Asterion

Antibody Drug Conjugates: Current and Future Developments by Hans-Peter Gerber, Ph.D., Senior Director Pfizer

Enhancing the Activities of Monoclonal Antibodies for Cancer Therapy by Peter Senter, Ph.D., Vice President Chemistry, Seattle Genetics

New Horizons in Protein Medicinal Chemistry Enabled with an Expanded Genetic Code by Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx Inc.

 

4th Annual Peptide Therapeutics Symposium, November 2009

Update on development trends for peptide therapeutics by Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development.

New Targets and Targeting Mechanisms for Contrast Agents and Therapeutics by Roger Tsien, Ph.D., HHMI Investigator& 2008 Nobel Laureate Chemistry, Professor Pharmacology, Chemistry and Biochemistry, UCSD.

NMR structural studies of drug receptors in membranes by Stanley Opella, Ph.D., Professor Chemistry and Biochemistry & Director Nuclear Magnetic Resonance Resource Lab, UCSD.

Peptide transduction domain mediated delivery of macromolecules; Tackling the siRNA delivery problem by Steven F. Dowdy, Ph.D., HHMI Investigator & Professor Cellular and Molecular Medicine, School of Medicine, UCSD

Peptide inhibitors of protein-protein interactions; From rational design to the clinic by Daria Mochly-Rosen, Ph.D., Professor, Chemical and Systems Biology & Senior Associate Dean for Research, School of Medicine, Stanford University.

Stapled helical peptides: A new drug modality by Noriyuki Kawahata Ph.D., Senior Principal Scientist Chemistry, Aileron Therapeutics.

Clinically validated inhibitors of intracellular protein interactions by Stephen D. Harrison, Ph.D., Senior Vice President, Research, Kai Pharmaceuticals.

Pepducins – Novel mediators of GPCR signaling by Stephen Hunt, Ph.D., Senior Vice President, Discovery Research, Ascent Therapeutics.

Linaclotide: A potential therapy for IBS-C by Mark G. Currie, Ph.D., Senior Vice President, R&D & CSO, Ironwood Pharmaceuticals Inc.

Non-Invasive systemic delivery of peptides with high bioavailability by Edward T. Maggio, Ph.D., CEO & Director, Aegis Therapeutics.

 

3rd Annual Peptide Therapeutics Symposium, October 2008

CovX-Body Biotherapeutics: From Concept to Applications by Joel Desharnais, Ph.D. Senior Scientist, CovX

Sustained Release of Peptides Using Microencapsulation and the Development of Long Acting Exenatide by Paul Herbert, Vice President Process Development Alkermes , Inc.
V1a Agonists in Vasodilatory Shock: From Bedside to Bench, and Back by Donald W. Landry, M.D., Ph.D., Chair, Department of Medicine, Columbia University
LAPSCOVERY Technology and Its Application to Long Acting Peptide/Protien Drugs by Gwan Sun Lee, Ph.D., Managing Research Director, Hanmi Research Center, Hanmi Pharm. Co., Ltd

Engineering Kunitz Domains Using Phage Display by Andrew E. Nixon, Ph.D., Vice President, Lead Discovery and Biochemistry, Dyax Corporation

Preformed Conjugate-Drug Affinity Complex (PC-DAC™) Technology by Martin Robitaille, Ph.D., Director, Peptide Chemistry, Conjuchem Biotechnologies, Inc.

Trends in the Clinical Development and Approval of Synthetic Peptides by Janice Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development

 

2nd Annual Peptide Therapeutics Symposium, November 2007

Building, Understanding and Leveraging a Peptide Library by Michael Hanley, Ph.D., Vice President Discovery Research, Amylin Pharmaceuticals

Application of Chemical Biotechnology to the Optimization of Protein Therapeutics by Richard Dimarchi, Ph.D., Professor, Department of Medicinal Chemistry, Indiana University

Degarelix: a novel GnRH antagonist for the treatment of prostate cancer by Per Cantor, M.D., Ph.D., Senior Vice President Clinical and Non-Clinical Development, Ferring Pharmaceuticals

KL-4 Surfactant – Form to Function by Charles Cochrane, M.D., Professor, Department of Immunology, The Scripps Research Institute

The Commercialization of Fuzeon® API by Brad DeHoff, Ph.D., Technical Manager, Roche Colorado Corp.

The Beta Cell Hormone Amylin: Discovery and Clinical Application by Andrew Young, M.D., Ph.D., Vice President , Senior Research Fellow, Amylin Pharmaceuticals

“Ynot Y2 and Y4 Peptide Agonists for Treatment of Diabetes and Obesity?” by Thue Schwartz, M.D., CSO, 7TM Pharma, University of Copenhagen

Oxyntomodulin or Products of the PYY Preproglucagon gene by Steve Bloom, M.D., Professor of Medicine, Imperial College, London

 

1st Annual Peptide Therapeutics Symposium, November 2006

Medicinal Chemistry of Peptide Hormones by Victor Hruby, Ph.D., Regents Professor of Chemistry, University of Arizona

GnRH: a Peptide for All Seasons by Robert Millar, Ph.D., Director, MRC Human Reproductive Sciences Unit, Ardana

Desmopressin, a Selective Antidiuretic Analog of Vasopressin by Jens Peter Norgaard, Ph.D., CSO, Urology, Ferring Pharmaceuticals
Osteoporosis, Regenerating Bone and Parathyroid Hormone by Michael Rosenblatt, Ph.D., Dean, Tufts University Medical School

History of the Development of Byetta: The Vicissitudes of Drug Development in Biotechnology by Alain D. Baron, Ph.D., Sr. Vice President, Research, Amylin Pharmaceuticals

Clinical Applications of the GLP-2 Analogue Teduglutide by Derek Chalmers, Ph.D., President  & CEO, Cara Therapeutics

Current Status of Methods for Large-Scale Production of Peptides Michael Verlander, Executive Vice President, Ph.D., Polypeptide Laboratories, Inc.

 

Symposium 1-5

For more information regarding Symposiums 1-5, please contact us.

News
Symposium

Peptide Therapeutic Foundation announces the winners of the Ferring Research Institute Innovation Grants program for 2017:

Stéphane Bolduc – CHU de Québec – Université Laval Research Center

Marcello Costa – Flinders University

Warren Foster – University of California, San Diego

Andrew Horne – University of Edinburgh

K. Joseph Hurt – University of Colorado

Ursula Kaiser – Brigham and Women’s Hospital, Harvard Medical School

Sarah Marshall – Monash University

Kathryn Meier – Washington State University

Victor Navarro – Brigham and Women’s Hospital, Harvard Medical School

Willis Samson – Saint Louis University, School of Medicine

John Taylor – Kansas University Medical Center

Suraj Unniappan – University of Saskatchewan

Henrique Veiga-Fernandes – Champalimaud Foundation

2016 Winners:
Stuart Brierley – Flinders University
James Deane – Hudson Institute of Medical Research
Laurent Derre – Centre Hospitalier Universitaire Vaudois
Renjie Jin– Vanderbilt University
Florenta Kullmann – University of Pittsburgh
Mireille Lahoud – Monash University
Padma Murthi – Monash University
Markus Muttenthaler – University of Queensland
Rodrigo Pacheco – Fundación Ciencia & Vida
Aritro Sen – University of Rochester Medical Center
Marie van Dijk – Academic Medical Center, University of Amsterdam

 

October 25-26, 2018

The 13th Annual Peptide
Therapeutics Sympsium

The Salk Institute
La Jolla, California

Sponsors